Wellgistics Health, Inc. Files Amendment No. 1 to Annual Report: Restatements and New Disclosures

Summary of Filing

Wellgistics Health, Inc. has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The Amendment was filed on April 24, 2026 and is an annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. This update is particularly important as it restates material sections of the original filing and incorporates new governance and compensation policies.

Key Points in the Report

• Restatement of Part III, Items 10 & 12: The company has restated these sections in their entirety, which relate to Directors, Executive Officers and Corporate Governance and Security Ownership of Certain Beneficial Owners and Management. This is a significant update, as restatements often indicate corrections or changes that could impact investor perceptions.
• Inclusion of New Exhibits: Additional exhibits have been incorporated, including the Clawback Policy, which addresses compensation recovery from executives in the event of accounting restatements or policy breaches. This policy aligns with new SEC requirements and may affect executive compensation and accountability.
• Reverse Stock Split Approval: The company disclosed that a reverse stock split was approved, as described in its Information Statement on Schedule 14C filed April 3, 2026. Reverse stock splits can affect share prices and investor holdings, and are often undertaken to meet minimum price requirements for continued listing.
• Note Purchase Agreement: Entry into a Note Purchase Agreement with certain investors was announced (April 7, 2026), potentially impacting the company’s capital structure and liquidity.
• Termination of Settlement Agreement: The company terminated its Settlement Agreement and Stipulation with Silverback Capital Inc. (April 9, 2026), which may affect ongoing legal and financial obligations.
• Share Count: As of March 6, 2026, the company reported 104,871,987 shares of common stock issued and outstanding. Changes in share count due to corporate actions such as splits or new issuances can impact shareholder value.

Governance and Compliance Updates

• Audit Committee: The composition and function of the Audit Committee comply with Sarbanes-Oxley Act, SEC rules, and Nasdaq requirements. Responsibilities include monitoring financial integrity, reviewing internal controls, and overseeing audit processes.
• Nominating and Compensation Committee: This committee is responsible for approving executive compensation, administering incentive plans, reviewing succession plans, and developing governance guidelines.
• Code of Ethics: The company has a code of ethics applicable to principal officers and intends to disclose material changes or waivers online or via SEC filings. Ethical compliance is critical for investor confidence.
• Insider Trading Policy: All employees, officers, and directors are subject to an insider trading policy, including anti-hedging provisions and trading windows. This policy is designed to prevent misuse of material nonpublic information and aligns interests between executives and shareholders.

Section 16(a) Compliance

All directors, executive officers, and >10% beneficial owners are required to file ownership reports with the SEC. The company notes that Prashant Patel, Suren Ajjarapu, and Eric Sherb failed to timely file a Form 3 upon becoming reporting persons, but subsequently rectified the issue.

Exhibits Incorporated by Reference

The Amendment includes several important exhibits, such as:

• Second Amended and Restated 2023 Equity Incentive Plan
• Underwriting Agreements
• Merger Agreements
• Promissory Notes
• Registration Rights Agreements
• Code of Ethics
• Insider Trading Policy
• Compensation Recovery (Clawback) Policy
• Certifications by executive officers

These documents outline the company’s financial, compensation, and governance framework, and their inclusion may signal enhanced transparency and compliance.

Potential Price-Sensitive Information

• Restatements of key governance and ownership sections—may signal prior inaccuracies or new information, which could affect investor confidence.
• Reverse stock split approval—can significantly affect share value and liquidity.
• New and terminated financial agreements—including Note Purchase Agreements and Settlement Agreements, may impact the company’s financial position.
• Clawback Policy and Insider Trading Policy—these enhance corporate governance and may affect executive behavior and compensation, contributing to improved shareholder alignment.

Conclusion

The Amendment No. 1 to Wellgistics Health, Inc.’s 10-K contains several material updates and new disclosures that are relevant for investors. The restatement of governance and ownership sections, reverse stock split, new financial agreements, and strengthened governance policies could all impact the company’s valuation and investor confidence. Shareholders should review these changes carefully, as they may affect both short-term trading and long-term investment decisions.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions. The article summarizes public filings and may not reflect the most current information or subsequent events affecting the company.

View Wellgistics Health, Inc. Historical chart here